Madrigal Pharmaceuticals, Inc. (MDGL) Stock

Madrigal Pharmaceuticals, Inc. (MDGL) is a Healthcare stock trading at $505.92 (as of 2026-06-18), with a market capitalization of $11.46B and a trailing P/E of -39.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Madrigal Pharmaceuticals, Inc. develops and commercializes therapeutic candidates focused on cardiovascular, metabolic, and liver diseases. Its lead candidate, resmetirom, is in Phase III for non-alcoholic steatohepatitis, and it also develops MGL-3745 as a backup; the company has a research, development, and commercialization agreement with Hoffmann-La Roche.

Valuation — source: SEC EDGAR (first-party)
Price	$505.92
Market Cap	$11.46B
P/E Ratio	-39.6
EV / EBITDA	-37.7
Price / Book	21.46
Price / Sales	10.30
DCF Value (model)	$-146.95
DCF Upside vs Price	-129.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$958.40M
Net Margin	-30.1%
Return on Equity	-56.9%
Debt / Equity	0.63
Current Ratio	3.50
Revenue Growth (YoY)	432.1%
EPS Growth (YoY)	-41.3%
FCF Growth (YoY)	-58.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	9.14 (safe)

Valuation vs Sector & Industry
Stock P/E	-39.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-288.8%
vs Industry	-329.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BAKER BROS. ADVISORS LP ($1.12B)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	William J. Sibold
Employees	528
Country	US
IPO Date	2007-02-06

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.